Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DTC Ad Final Rule Means Reliance On PhRMA Program Risks Enforcement Action – Azar

Executive Summary

Nevertheless, the Pharmaceutical Research and Manufacturers of America announces enhancement of its voluntary drug pricing disclosures program, a Medicines Assistance Tool website that links to individual company sites, in response to the US rule.

You may also be interested in...



DTC Ad Proposal: Biopharma, Advertisers Marshall Legal Arguments In Opposition

Industry comments urge CMS to withdraw proposed rule mandating list price disclosures in TV ads, citing legal conflicts.

Trump Administration's Rx Drug Price Disclosure Reg Seen As Unworkable

Lawyers say CMS proposed rule requiring TV ads to disclose drug's list price wouldn't survive First Amendment suit and competitors have no reason to try to enforce it.

Trump Administration's Rx-Price-Disclosure Reg Sets Up Legal Fight With PhRMA

From kinds of ads targeted to agency that's issuing the reg, policy seems designed to withstand a court challenge.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel